Delay to implement antithrombotic and/or antiarrhythmic drugs for the supraventricular arrhythmia. 12-month [clinicaltrials_resource:e629a8816327fc89b7d730953c88efe3]
Delay from enrollment until the next in-office follow-up during which the supraventricular arrhythmia is managed for the first-time.
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]
Delay to implement antithrombotic and/or antiarrhythmic drugs for the supraventricular arrhythmia. 12-month [clinicaltrials_resource:e629a8816327fc89b7d730953c88efe3]
Delay from enrollment until the next in-office follow-up during which the supraventricular arrhythmia is managed for the first-time.
Bio2RDF identifier
e629a8816327fc89b7d730953c88efe3
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:e629a8816327fc89b7d730953c88efe3
measure [clinicaltrials_vocabulary:measure]
Delay to implement antithrombo ...... e supraventricular arrhythmia.
time frame [clinicaltrials_vocabulary:time-frame]
description
Delay from enrollment until th ...... is managed for the first-time.
identifier
clinicaltrials_resource:e629a8816327fc89b7d730953c88efe3
title
Delay to implement antithrombo ...... ntricular arrhythmia. 12-month
@en
type
label
Delay to implement antithrombo ...... 9a8816327fc89b7d730953c88efe3]
@en